title: Galectin-3 inhibition suppresses drug resistance, motility, invasion and angiogenic potential in ovarian cancer.
abstract: OBJECTIVE
  Ovarian cancer is the most deadly gynecologic malignancy worldwide. Since the pathogenesis of ovarian cancer is incompletely understood, and there are no available screening techniques for early detection, most patients are diagnosed with advanced, incurable disease. In an effort to develop innovative and effective therapies for ovarian cancer, we tested the effectiveness of Galecti-3C in vitro. This is a truncated, dominant negative form of Galectin-3, which is thought to act by blocking endogenous Galectin-3.
  
  
  METHODS
  We produced a truncated, dominant-negative form of Galectin-3, namely Galetic-3C. Ovarian cancer cell lines and primary cells from ovarian cancer patients were treated with Galectin-3C, and growth, drug sensitivity, and angiogenesis were tested.
  
  
  RESULTS
  We show, for the first time, that Galectin-3C significantly reduces the growth, motility, invasion, and angiogenic potential of cultured OC cell lines and primary cells established from OC patients.
  
  
  CONCLUSIONS
  Our findings indicate that Galectin-3C is a promising new compound for the treatment of ovarian cancer.
authors.affiliation: Department of Internal Medicine at the Division of Hematology & Oncology & Oncology, The Southwest Cancer Treatment and Research Center, Texas Tech University Health Sciences Center, Lubbock, TX, USA; Laura W Bush Institute for Women's Health and Center for Women's Health and Gender-Based Medicine, Amarillo, TX, USA.
authors.forename: Leonardo
authors.initials: L
authors.lastname: Mirandola
authors.affiliation: Department of Internal Medicine at the Division of Hematology & Oncology & Oncology, The Southwest Cancer Treatment and Research Center, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
authors.forename: Yuefei
authors.initials: Y
authors.lastname: Yu
authors.affiliation: University of Arkansas for Medical Sciences, Department of Obstetrics and Gynecology, Little Rock, AR, USA.
authors.forename: Martin J
authors.initials: MJ
authors.lastname: Cannon
authors.affiliation: Laura W Bush Institute for Women's Health and Center for Women's Health and Gender-Based Medicine, Amarillo, TX, USA.
authors.forename: Marjorie R
authors.initials: MR
authors.lastname: Jenkins
authors.affiliation: Division of Surgical Oncology, Texas Tech University Medical Center, Amarillo, TX, USA.
authors.forename: Rakhshanda L
authors.initials: RL
authors.lastname: Rahman
authors.affiliation: Department of Internal Medicine at the Division of Hematology & Oncology & Oncology, The Southwest Cancer Treatment and Research Center, Texas Tech University Health Sciences Center, Lubbock, TX, USA; Kiromic, Inc., Lubbock, TX, USA.
authors.forename: Diane D
authors.initials: DD
authors.lastname: Nguyen
authors.affiliation: Humanitas Clinical and Research Center, Milano, Italy.
authors.forename: Fabio
authors.initials: F
authors.lastname: Grizzi
authors.affiliation: Department of Internal Medicine at the Division of Hematology & Oncology & Oncology, The Southwest Cancer Treatment and Research Center, Texas Tech University Health Sciences Center, Lubbock, TX, USA; Laura W Bush Institute for Women's Health and Center for Women's Health and Gender-Based Medicine, Amarillo, TX, USA; Kiromic, Inc., Lubbock, TX, USA.
authors.forename: Everardo
authors.initials: E
authors.lastname: Cobos
authors.affiliation: Department of Internal Medicine at the Division of Hematology & Oncology & Oncology, The Southwest Cancer Treatment and Research Center, Texas Tech University Health Sciences Center, Lubbock, TX, USA; Kiromic, Inc., Lubbock, TX, USA.
authors.forename: Jose A
authors.initials: JA
authors.lastname: Figueroa
authors.affiliation: Department of Internal Medicine at the Division of Hematology & Oncology & Oncology, The Southwest Cancer Treatment and Research Center, Texas Tech University Health Sciences Center, Lubbock, TX, USA; Laura W Bush Institute for Women's Health and Center for Women's Health and Gender-Based Medicine, Amarillo, TX, USA; Kiromic, Inc., Lubbock, TX, USA.
authors.forename: Maurizio
authors.initials: M
authors.lastname: Chiriva-Internati
mesh_terms: D017209:Apoptosis / Q000187:drug effects; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects; D018572:Disease-Free Survival; D019008:Drug Resistance, Neoplasm; D005260:Female; D037502:Galectin 3 / Q000037:antagonists & inhibitors*; D061307:Human Umbilical Vein Endothelial Cells; D006801:Humans; D009361:Neoplasm Invasiveness; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D010051:Ovarian Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000473:pathology
chemical_list: D037502:Galectin 3
keywords: Angiogenesis; Galectin-3; Galectin-3C; Invasion; Ovarian cancer